Trametinib, as a monotherapy, first received its FDA approval for the treatment of some melanomas carrying certain BRAF mutations and was subsequently approved as a combinational therapy for some solid tumors including gliomas and NSCLC. This evidence concerns the gene BRAF and central nervous system cancer.